OK, fine -- though why you think Teva might make a deal with a 3rd party with no expertise is beyond me . . . so how would you ask the question? Do you think it's worth the bother of asking? I think it is much less likely you'll get an answer to this than I was in getting an answer about inspections. Though you might get a categorical No.
Suppose they surprise me and reveal the third party. How do we know the 3rd party has no expertise? Looking at its patent estate? By noting the absence of any MIT grads in their upper research management team? We've pretty much concluded it's mostly trade secret, anyway.
SmithKline was fiddling with oligosaccharide characterization in the late 90s . . .
"After reviewing the FDA’s response to the citizen’s petition, which outlines 5 criteria to demonstrate "sameness", Teva believes that it has demonstrated to the FDA that its version of generic Lovenox meets their criteria and that Teva’s pending ANDA is approvable."
Do we care if it is Teva's project or someone else' if this is true?
Good luck! Let's hope it's Natco.
Regards, RockRat
Market Data 
Markets 
AI
